Business
The Effects of ProtoKinetix’ Anti-Aging Glycopeptide (AAGP™) on Immune Cell Banking and Functions Relevant to Immunotherapy
The Effects of ProtoKinetix’ Anti-Aging Glycopeptide (AAGP™) on Immune Cell Banking and Functions Relevant to Immunotherapy.
About this update from Protokinetix, Inc.
[{"type":"text","content":"\n \n ProtoKinetix, Incorporated (www.protokinetix.com) \n (the \"Company\" or \"ProtoKinetix\") (OTCQB:PKTX) \n is pleased to provide a scientific update on immune cell banking and \n functions relevant to immunotherapy using AAGP™ in collaboration with \n Proactive Immune Sciences. Earlier in 2017, Proactive initiated a \n research program which utilized an anti-aging glycopeptide (AAGP™) \n produced by ProtoKinetix Inc. which, amongst other uses, has shown the \n potential to benefit various cells during cryopreservation. In this \n research program, Proactive is investigating whether the AAGP™ produced \n by ProtoKinetix Inc. improves survival and function of cryopreserved \n immune cells by focusing on the following objective:\n \n \n 1) Assessment of the effect of AAGP™ on cryopreserved immune cell \n viability and functionality.\n \n \n Immune based interventions represent one of the fastest growing, most \n promising areas of personalized medicine. This is particularly true for \n cancer, which is largely a disease of immune failure. Therefore, there \n is a strong impetus for individuals to bank healthy immune cells at as \n early an age as possible, before these cells are compromised by \n infection, malignancy, or simply advanced immunological age. Proactive \n Immune Sciences Corporation will collect and cryopreserve all of the \n different types of immune cells present in blood for its clients. These \n cells can be used later for any form of immunotherapy the client might \n require. These cells can also be used for immune system regeneration to \n help restore an immune system that is compromised from chemotherapy or \n radiation treatments or even old age. Although cryopreservation of cells \n is commonly performed, Proactive would like to offer its clients the \n most advanced methods to ensure their cells are in optimal conditions \n for the processing required for these immunotherapies.\n \n \n In May 2017, Proactive, with the support of the National Research \n Council of Canada (NRC) through an Industrial Research Assistance \n Program (IRAP) Grant, began testing AAGP™ in the cryopreservation \n process used to store Peripheral Blood Mononuclear Cells (PBMC). Cells \n were frozen using Proactive’s cryopreservation “cocktail” along with \n various concentrations...